The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Clinical Cancer Research

• Publication date

  2000-04-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  PMID 10778948
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.

  1998influential reference
• CYP3A4 and the erythromycin breath test

  1998cited by this paper
• Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency.

  1997cited by this paper
• Optimal sampling strategies for bayesian estimation of docetaxel (Taxotere) clearance.

  1997cited by this paper
• A population pharmacokinetic model for docetaxel (Taxotere): model building and validation.

  1996cited by this paper
• Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans.

  1996cited by this paper
• Docetaxel (Taxotere) in the treatment of solid tumors other than breast and lung cancer.

  1995cited by this paper
• The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions.

  1995cited by this paper
• PREDICTION OF INTERPATIENT AND INTRAPATIENT VARIATION IN OG 37–325 DOSING REQUIREMENTS BY THE ERYTHROMYCIN BREATH TEST

  1994cited by this paper
• Phase II study with Docetaxel (Taxotere®) in advanced soft tissue sarcomas of the adult

  1994cited by this paper
• Noninvasive tests of CYP3A enzymes.

  1994influential reference
• Determination of Taxotere in human plasma by a semi-automated high-performance liquid chromatographic method.

  1992cited by this paper

• Pollutants and Cancer Therapy.

  2026cites this paper
• Cannabinoids in Combination with Conventional Breast Cancer Therapies: Mechanistic Insights and the Gap to Clinical Translation

  2026cites this paper
• Docetaxel-Induced Toxicities in Patients With Breast Cancer With CYP3A4*22 Alleles

  2026cites this paper
• Hepatotoxicity of Chemotherapy and Immune Checkpoint Inhibitors.

  2025cites this paper
• Docetaxel Resistance in Breast Cancer: Current Insights and Future Directions

  2025cites this paper
• Opportunities for Precision Dosing of Cytotoxic Drugs in Non-Small Cell Lung Cancer: Bridging the Gap in Precision Medicine

  2025cites this paper
• A sub-pharmacological test dose does not predict individual docetaxel exposure in prostate cancer patients

  2024cites this paper
• Using maximum plasma concentration (Cmax) to personalize taxane treatment and reduce toxicity

  2024cites this paper
• Profiling Docetaxel in Plasma and Urine Samples from a Pediatric Cancer Patient Using Ultrasound-Assisted Dispersive Liquid–Liquid Microextraction Combined with LC–MS/MS

  2023cites this paper
• Activation/Inactivation of Anticancer Drugs by CYP3A4: Influencing Factors for Personalized Cancer Therapy

  2023cites this paper
• Identification of Cytochrome P450 Enzymes Responsible for Oxidative Metabolism of Synthetic Cannabinoid (1-Hexyl-1H-Indol-3-yl)-1-naphthalenyl-methanone (JWH-019)

  2023cites this paper
• Suspected Neratinib Macular Toxicity Presenting As Macular Telangiectasia Type II

  2023cites this paper
• ATVB IN FOCUS: Dynamic Functionality of Apolipoproteins

  2023cites this paper
• Life-Threatening Docetaxel Toxicity in a Patient With Reduced-Function CYP3A Variants: A Case Report

  2022cites this paper
• Association between gene polymorphism and adverse effects in cancer patients receiving docetaxel treatment: a meta-analysis

  2022influential citation
• Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients

  2022cites this paper
• CYP3A4∗22 Genotyping in Clinical Practice: Ready for Implementation?

  2021cites this paper
• Tumour Microenvironment Stress Promotes the Development of Drug Resistance

  2021influential citation
• Influence of Concomitant Polypharmacy on Docetaxel-induced Febrile Neutropenia.

  2021cites this paper
• Traditional herbal medicine and nanomedicine: Converging disciplines to improve therapeutic efficacy and human health.

  2021cites this paper
• Enhanced Activity of P4503A4 and UGT1A10 Induced by Acridinone Derivatives C-1305 and C-1311 in MCF-7 and HCT116 Cancer Cells: Consequences for the Drugs’ Cytotoxicity, Metabolism and Cellular Response

  2020cites this paper
• Role of TDM‐based dose adjustments for taxane anticancer drugs

  2020cites this paper
• [Does the FLOT regimen a new standard of perioperative chemotherapy for localized gastric cancer?]

  2020cites this paper
• Analysis on risk factors of myelosuppression caused by nedaplatin in patients with lung cancer

  2020cites this paper
• Resistance to Anti-angiogenic Therapies: A Mechanism Depending on the Time of Exposure to the Drugs

  2020cites this paper
• Delivery of Docetaxel to Brain Employing Piperine-Tagged PLGA-Aspartic Acid Polymeric Micelles: Improved Cytotoxic and Pharmacokinetic Profiles

  2019cites this paper
• Principles of Dose, Schedule, and Combination Therapy

  2019cites this paper
• Principles of Chemotherapy in Older Adults

  2019cites this paper
• General Discussion and Future Perspectives

  2019cites this paper
• Simultaneous Assessment of Hepatic Transport and Metabolism Pathways with a Single Probe Using Individualized PBPK Modeling of 14CO2 Production Rate Data

  2019influential citation
• Pharmacogenetic impact of docetaxel on neoadjuvant treatment of breast cancer patients.

  2018cites this paper
• Targeting the tumour stroma to improve cancer therapy

  2018cites this paper
• Application of liquid chromatography-tandem mass spectrometry to study the effect of docetaxel on pharmacokinetics and tissue distribution of apatinib in mice.

  2018cites this paper
• Docetaxel-Loaded Lecithoid Nanoparticles with Enhanced Lung Targeting Efficiency and Reduced Systemic Toxicity: Developed by Solid Dispersion and Effervescent Techniques.

  2017cites this paper
• Regulation of Drug-Metabolizing Enzymes and Drug Metabolism by Inflammatory Responses

  2017cites this paper
• Nano-sized cytochrome P450 3A4 inhibitors to block hepatic metabolism of docetaxel

  2017cites this paper
• Potential use of Aneustat for improvement of docetaxel-based therapy of advanced prostate cancer

  2017cites this paper
• Pharmacological and Interventional Approaches for Optimizing Taxane Treatment

  2016cites this paper
• Integrin Receptors Play a Key Role in the Regulation of Hepatic CYP3A

  2016influential citation
• Role of pharmacogenetics for the improvement of cancer treatment

  2016cites this paper
• The relevance of using 3D cell cultures, in addition to 2D monolayer cultures, when evaluating breast cancer drug sensitivity and resistance

  2016cites this paper
• Outcomes of re-treatment with first-line trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo)adjuvant trastuzumab: A prospective multicenter study

  2016cites this paper
• Metabolism and excretion of novel pulmonary-targeting docetaxel liposome in rabbits

  2016cites this paper
• Drugs of abuse and addiction: A slippery slope toward liver injury.

  2016cites this paper
• The role of CYP 3A4 and 1A1 in amiodarone-induced hepatocellular toxicity.

  2016cites this paper
• The Effect of Undaria pinnatifida Fucoidan on the Pharmacokinetics of Letrozole and Tamoxifen in Patients With Breast Cancer

  2016cites this paper
• 4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes.

  2015cites this paper
• Clinical Pharmacokinetics of the Novel Combination of BEZ235, PI3K/mTOR Inhibitor, and Everolimus, mTOR Inhibitor: Phase I Clinical Studies and Non-clinical Mechanistic Assessment

  2015cites this paper
• Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose

  2015cites this paper
• d'un essai de phase I

  2015cites this paper
• Inhibition of human cytochrome P450 enzymes by licochalcone A, a naturally occurring constituent of licorice.

  2015cites this paper
• Discovery of Cytotoxic Dolastatin 10 Analogues with N-Terminal Modifications

  2015cites this paper
• Dose optimization of oral targeted therapies in oncology

  2015cites this paper
• Inter-patient variability in docetaxel pharmacokinetics: A review.

  2015influential citation
• Docetaxel Induced Sclerosing Cholangitis

  2015cites this paper
• Étude de la pharmacocinétique du pazopanib en association avec le cisplatine à partir de données issues d'un essai de phase I

  2014cites this paper
• Discovery of cytotoxic dolastatin 10 analogues with N-terminal modifications.

  2014cites this paper
• Conventional Dosing of Anticancer Agents: Precisely Wrong or Just Inaccurate?

  2014cites this paper
• Frequency distribution of high risk alleles of CYP2C19, CYP2E1, CYP3A4 genes in Haryana population.

  2014cites this paper
• Synthesis of ¹³C-lidocaine as a probe of breath test for the evaluation of cytochrome P450 activity.

  2014cites this paper
• The Scientific Basis of Body Surface Area–Based Dosing

  2014cites this paper
• СТАБИЛЬНО-ИЗОТОПНАЯ ДИАГНОСТИКА В РОССИИ: ИТОГИ И ПЕРСПЕКТИВЫ. 13 С-ПРЕПАРАТЫ, ПРИБОРЫ, МЕТОДЫ

  2014cites this paper
• Results From the Phase III Trial CLEOPATRA Asia With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Safety Profile of Pertuzumab With Trastuzumab and Docetaxel in Patients From

  2014cites this paper
• Drug-Induced Liver Injury due to Cancer Chemotherapeutic Agents

  2014cites this paper
• The reduction of anti-cancer drug antagonism by the spatial protection of drugs with PLA-TPGS nanoparticles.

  2014cites this paper
• Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA.

  2014cites this paper
• FACULTE MIXTE DE MEDECINE ET DE PHARMACIE DE ROUEN

  2013influential citation
• Pharmacology of aging and cancer: how useful are pharmacokinetic tests?.

  2013cites this paper
• Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy.

  2013cites this paper
• Midazolam as a phenotyping probe to predict sunitinib exposure in patients with cancer

  2013cites this paper
• Breath Tests to Phenotype Drug Disposition in Oncology

  2013cites this paper
• Pharmacogenetic predictors of taxane-induced peripheral neuropathy

  2013cites this paper
• Chemotherapy-induced hepatotoxicity.

  2013cites this paper
• Anti-proliferative actions of N'-desmethylsorafenib in human breast cancer cells.

  2013cites this paper
• Risk-adapted, dose escalation study of weekly docetaxel in the first-line treatment of elderly patients with advanced cancer.

  2013cites this paper
• Chemotherapy in Older Adults with Cancer

  2013cites this paper
• CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin.

  2013cites this paper
• Lentiviral Transgenic MicroRNA-Based shRNA Suppressed Mouse Cytochromosome P450 3A (CYP3A) Expression in a Dose-Dependent and Inheritable Manner

  2012cites this paper
• OATP1B1 Polymorphism as a Determinant of Erythromycin Disposition

  2012cites this paper
• Personalising docetaxel and G-CSF schedules in cancer patients by a clinically validated computational model

  2012influential citation
• Impact de l'obésité et de la composition corporelle sur la toxicité du Docetaxel : étude rétrospective sur 200 patientes traitées entre 2008 et 2010 au centre Henri Becquerel pour un cancer du sein localisé

  2012cites this paper
• THESE POUR LE DOCTORAT EN MEDECINE

  2012cites this paper
• CYP3A genotypes in Bangladeshi tuberculosis patients.

  2012cites this paper
• Phenotyping drug disposition in oncology.

  2012cites this paper
• Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours.

  2012cites this paper
• Pilot study of rosiglitazone as an in vivo probe of paclitaxel exposure.

  2012cites this paper
• Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer

  2011cites this paper
• Taxane doublets for metastatic breast cancer: do we need another cytotoxic pair or another approach?

  2011cites this paper
• Therapeutic Drug Monitoring for the Individualization of Docetaxel Dosing: A Randomized Pharmacokinetic Study

  2011cites this paper
• Level of evidence for therapeutic drug monitoring of taxanes

  2011cites this paper
• Pharmacogenetics in Ghana: reviewing the evidence.

  2011cites this paper
• Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C14-erythromycin breath test and the antipyrine clearance test

  2011influential citation
• CHIP and gp78-mediated ubiquitination of CYP3A4

  2011cites this paper
• Similarities and Differences in the Expression of Drug-Metabolizing Enzymes between Human Hepatic Cell Lines and Primary Human Hepatocytes

  2011cites this paper
• Studies to Understand the Effect of Cancer on Hepatic CYP2C19 Activity

  2011cites this paper
• The use of 13C-erythromycin as an in vivo probe to evaluate CYP3A-mediated drug interactions in rats.

  2011cites this paper
• Lack of effect of casopitant on the pharmacokinetics of docetaxel in patients with cancer

  2011cites this paper
• Genotypes and phenotypes of CYP3A in Bangladeshi population.

  2011cites this paper
• NCT01110291: induction of CYP3A activity and lowered exposure to docetaxel in patients with primary breast cancer

  2011cites this paper
• Effect of grapefruit juice on the pharmacokinetics of docetaxel in cancer patients: a case report.

  2011cites this paper